Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

28.64 -0.22 (-0.76%)
Official Closing Price Updated: 7:00 PM EDT, Oct 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 31,473,595
Open 28.86
Bid (Size) 28.66 (19)
Ask (Size) 28.67 (60)
Prev. Close 28.86
Today's Range 28.50 - 28.98
52wk Range 25.20 - 31.54
Shares Outstanding 5,606,688,356
Dividend Yield 5.73%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for millions at risk of serious disease. 
Via Benzinga
CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines
The CDC recommends expanding pneumococcal vaccine eligibility to adults aged 50 and above, impacting disease prevention with Pfizer and Merck's vaccines. 
Via Benzinga

Performance

YTD
-3.67%
-3.67%
1 Month
-2.92%
-2.92%
3 Month
-5.10%
-5.10%
6 Month
+13.38%
+13.38%
1 Year
-6.80%
-6.80%

More News

Read More
5 High-Yield Dividend Stocks to Buy Without Hesitation
Via The Motley Fool
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Via Benzinga
Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older
From Pfizer Inc.
Via Business Wire
Key Takeaways From Pfizer Analyst Ratings
Via Benzinga
A Closer Look at Pfizer's Options Market Dynamics
Via Benzinga
FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years
Via Benzinga
Exposures Product Safety
The Best Pharmaceutical Stock to Invest $1,000 in Right Now
Via The Motley Fool
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
From Pfizer Inc.
Via Business Wire
Activist Investor Starboard Slams Pfizer for Underperforming R&D And Overpaying for Acquisitions
Via Benzinga
Exposures COVID-19
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
Via Benzinga
Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises
Via Investor's Business Daily
Do Billionaires Israel Englander and Ken Griffin Know Something? Each Just Bought This Plagued Value Stock.
Via The Motley Fool
Nvidia Among Five Best S&P 500 Stocks Today
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Three AI Stocks That Could Beat Nvidia After Today
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
1 Ultra-High-Yield Healthcare Stock to Buy Hand Over Fist and 1 to Avoid
Via The Motley Fool
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Via The Motley Fool
3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now
Via The Motley Fool
Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Guggenheim's Longstanding Pfizer Ties Tested Amid Starboard Battle
Via Benzinga
Why I'm Considering Leaning Heavily Into Pfizer
Via The Motley Fool
GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Tim Buckley Elected to Pfizer’s Board of Directors
From Pfizer Inc.
Via Business Wire
Pfizer Is Clashing With Its New Activist Investor. Will It Harm The Stock?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.